• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

更年期潮热的管理。西班牙更年期协会的建议。

Management of menopausal hot flushes. Recommendations from the Spanish Menopause Society.

作者信息

Fasero M, Sanchez M, Baquedano L, Gippini I, Fuentes D, Navarro C, Beltrán E, Lilue M, Porcel I, Pingarrón C, Herrero M, Romero P, Ortega T, Carretero E, Palacios S, Mendoza N, Coronado P J

机构信息

Department of Obstetrics and Gynecology, Menopause Unit. Hospital de la Zarzuela. Universidad Francisco de Vitoria, Madrid Spain.

Clínica Corofas Menopause, Madrid, Spain.

出版信息

Eur J Obstet Gynecol Reprod Biol X. 2025 Jan 23;25:100366. doi: 10.1016/j.eurox.2025.100366. eCollection 2025 Mar.

DOI:10.1016/j.eurox.2025.100366
PMID:39944633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11814524/
Abstract

This project aims to develop recommendations for treating vasomotor symptoms (VMS) based on the Cervantes short-form scale score (menopausal domain) using the best available evidence. A total of 166 studies were selected: 108 randomized controlled trials, 23 systematic reviews, 3 reviews, 3 meta-analyses, 11 case-control studies, 9 observational studies, and 12 transversal studies. To achieve this objective, a series of PICO (Patient, Intervention, Comparison, and Outcome) questions have been established for the treatment of VMS. We evaluate the quality of the scientific evidence and, with the findings, create a decision framework to treat hot flashes based on the Cervantes short-form scale score.

摘要

本项目旨在利用现有最佳证据,制定基于塞万提斯简表评分(更年期领域)治疗血管舒缩症状(VMS)的建议。共筛选出166项研究:108项随机对照试验、23项系统评价、3项综述、3项荟萃分析、11项病例对照研究、9项观察性研究和12项横断面研究。为实现这一目标,针对VMS的治疗制定了一系列PICO(患者、干预措施、对照和结局)问题。我们评估科学证据的质量,并根据研究结果创建一个基于塞万提斯简表评分治疗潮热的决策框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f51f/11814524/15256f8e17d6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f51f/11814524/15256f8e17d6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f51f/11814524/15256f8e17d6/gr1.jpg

相似文献

1
Management of menopausal hot flushes. Recommendations from the Spanish Menopause Society.更年期潮热的管理。西班牙更年期协会的建议。
Eur J Obstet Gynecol Reprod Biol X. 2025 Jan 23;25:100366. doi: 10.1016/j.eurox.2025.100366. eCollection 2025 Mar.
2
Hot flushes and night sweats are associated with coronary heart disease risk in midlife: a longitudinal study.热潮和盗汗与中年时期的冠心病风险相关:一项纵向研究。
BJOG. 2015 Oct;122(11):1560-7. doi: 10.1111/1471-0528.13163. Epub 2014 Nov 7.
3
Phytoestrogens for menopausal vasomotor symptoms.植物雌激素用于治疗更年期血管舒缩症状。
Cochrane Database Syst Rev. 2013 Dec 10;2013(12):CD001395. doi: 10.1002/14651858.CD001395.pub4.
4
Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.非甾体选择性雌激素受体调节剂 fezolinetant 缓解与绝经相关血管舒缩症状的有效性和安全性:系统评价和 Meta 分析。
Eur J Obstet Gynecol Reprod Biol. 2024 Jun;297:142-152. doi: 10.1016/j.ejogrb.2024.04.017. Epub 2024 Apr 15.
5
Chinese herbal medicine for menopausal symptoms.用于缓解更年期症状的中草药
Cochrane Database Syst Rev. 2016 Mar 15;3(3):CD009023. doi: 10.1002/14651858.CD009023.pub2.
6
Protocol for systematic review and meta-analysis: hop (Humulus lupulus L.) for menopausal vasomotor symptoms.系统评价与荟萃分析方案:啤酒花(Humulus lupulus L.)用于治疗更年期血管舒缩症状
BMJ Open. 2016 Apr 22;6(4):e010734. doi: 10.1136/bmjopen-2015-010734.
7
Effect of omega-3 supplements on vasomotor symptoms in menopausal women: A systematic review and meta-analysis.ω-3 补充剂对绝经后妇女血管舒缩症状的影响:系统评价和荟萃分析。
Eur J Obstet Gynecol Reprod Biol. 2018 Sep;228:295-302. doi: 10.1016/j.ejogrb.2018.07.008. Epub 2018 Jul 20.
8
Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.血管舒缩性更年期症状与心血管疾病风险:六项前瞻性研究的汇总分析。
Am J Obstet Gynecol. 2020 Dec;223(6):898.e1-898.e16. doi: 10.1016/j.ajog.2020.06.039. Epub 2020 Jun 23.
9
Exercise for vasomotor menopausal symptoms.针对血管舒缩性更年期症状的运动
Cochrane Database Syst Rev. 2014 Nov 28;2014(11):CD006108. doi: 10.1002/14651858.CD006108.pub4.
10
Bioidentical hormones for women with vasomotor symptoms.用于有血管舒缩症状女性的生物同源激素。
Cochrane Database Syst Rev. 2016 Aug 1;2016(8):CD010407. doi: 10.1002/14651858.CD010407.pub2.

引用本文的文献

1
How effective is acupuncture in treating hot flashes in breast cancer patients? A systematic review and meta-analysis.针刺疗法对乳腺癌患者潮热症状的治疗效果如何?一项系统评价与荟萃分析。
Front Oncol. 2025 Mar 17;15:1543938. doi: 10.3389/fonc.2025.1543938. eCollection 2025.
2
Perspective: Isoflavones-Intriguing Molecules but Much Remains to Be Learned about These Soybean Constituents.观点:异黄酮——有趣的分子,但关于这些大豆成分仍有许多有待了解之处。
Adv Nutr. 2025 May;16(5):100418. doi: 10.1016/j.advnut.2025.100418. Epub 2025 Mar 27.

本文引用的文献

1
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials.依林扎奈坦治疗绝经相关血管舒缩症状:OASIS 1和2随机临床试验
JAMA. 2024 Aug 22;332(16):1343-54. doi: 10.1001/jama.2024.14618.
2
Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).在东亚女性中,fezolinetant 治疗与绝经相关的中度至重度血管舒缩症状的疗效和安全性:一项 3 期随机研究(MOONLIGHT I)。
J Int Med Res. 2024 May;52(5):3000605241247684. doi: 10.1177/03000605241247684.
3
Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
中文女性绝经相关血管舒缩症状使用 fezolinetant 的长期安全性:3 期开放标签 MOONLIGHT 3 临床试验。
J Int Med Res. 2024 May;52(5):3000605241246624. doi: 10.1177/03000605241246624.
4
Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.非甾体选择性神经激肽 3(NK3)受体拮抗剂 fezolinetant 治疗绝经相关血管舒缩症状对睡眠障碍和损害的影响。
Maturitas. 2024 Aug;186:107999. doi: 10.1016/j.maturitas.2024.107999. Epub 2024 May 15.
5
Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.OASIS 1 和 2 设计:评估 elinzanetant 治疗与绝经相关血管舒缩症状的疗效和安全性的 3 期临床试验。
Menopause. 2024 Jun 1;31(6):522-529. doi: 10.1097/GME.0000000000002350. Epub 2024 Apr 3.
6
Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).非佐利奈坦治疗绝经相关中重度血管舒缩症状:两项 3 期研究(SKYLIGHT 1 和 2)中内在和外在因素的影响。
Menopause. 2024 Apr 1;31(4):247-257. doi: 10.1097/GME.0000000000002340.
7
Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.非佐利奈坦对绝经相关血管舒缩症状的健康相关生活质量的影响:来自 SKYLIGHT 1 和 SKYLIGHT 2 随机对照试验的汇总数据。
BJOG. 2024 Aug;131(9):1296-1305. doi: 10.1111/1471-0528.17773. Epub 2024 Feb 6.
8
Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.非甾体类选择性雌激素受体调节剂费洛司腾特治疗与绝经相关血管舒缩症状的疗效和安全性:一项荟萃分析。
Obstet Gynecol. 2024 Mar 1;143(3):393-402. doi: 10.1097/AOG.0000000000005508. Epub 2024 Jan 16.
9
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.系统评价和网络荟萃分析比较非激素疗法 fezolinetant 与激素和非激素疗法治疗绝经相关血管舒缩症状的疗效。
Menopause. 2024 Jan 1;31(1):68-76. doi: 10.1097/GME.0000000000002281. Epub 2023 Nov 27.
10
The 2023 nonhormone therapy position statement of The North American Menopause Society.北美绝经学会 2023 年非激素治疗立场声明。
Menopause. 2023 Jun 1;30(6):573-590. doi: 10.1097/GME.0000000000002200.